Who are Doridamina's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MACRODANTIN.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lonidamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Doridamina — Competitive Intelligence Brief

Doridamina (LONIDAMINE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: lonidamine. Area: Oncology.

discontinued lonidamine Mitochondrial pyruvate carrier 2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Doridamina (LONIDAMINE). Doridamina works by inhibiting the mitochondrial pyruvate carrier 2, which is involved in the production of energy within cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Doridamina TARGET	LONIDAMINE		discontinued	lonidamine	Mitochondrial pyruvate carrier 2
MACRODANTIN	NITROFURANTOIN, MACROCRYSTALLINE	ALMATICA	marketed	Nitrofuran Antibacterial [EPC]	Mitochondrial pyruvate carrier 2, CDGSH iron-sulfur domain-containing protein 1, Glucose-6-phosphate 1-dehydrogenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (lonidamine class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Doridamina — Competitive Intelligence Brief. https://druglandscape.com/ci/lonidamine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab